sorafenib has been researched along with procyanidin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (procyanidin) | Trials (procyanidin) | Recent Studies (post-2010) (procyanidin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 4,116 | 136 | 2,747 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, K; Dai, W; Feng, J; Guo, C; Ji, J; Mao, Y; Wang, F; Wu, J; Wu, L; Xu, L; Yu, Q; Zhang, J | 1 |
1 other study(ies) available for sorafenib and procyanidin
| Article | Year |
|---|---|
PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; Heterografts; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Membrane Proteins; Mice; Proanthocyanidins; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2019 |